1. Introduction
===============

Zebrafish have been identified as a valuable whole animal platform for phenotypic screening at various stages of the drug discovery process \[[@b1-marinedrugs-08-01769]--[@b4-marinedrugs-08-01769]\]. Some of the advantages that zebrafish offer in laboratory assays include the transparency of their embryos, allowing direct observation of organ morphology during treatment or visualization of specific molecular species using hybridization techniques; rapid development and short reproductive cycles; and easy maintenance in 96-well plates. Although the potential value of zebrafish in screening natural product extract libraries has been noted \[[@b5-marinedrugs-08-01769],[@b6-marinedrugs-08-01769] \], to date relatively few zebrafish-based natural product screening programs, from either plants or marine sources, have been reported \[[@b7-marinedrugs-08-01769]--[@b9-marinedrugs-08-01769]\]. As part of a pilot study, we screened a prefractionated extract library \[[@b10-marinedrugs-08-01769]\] from marine invertebrates for zebrafish phenotypic activity. This small library included four fractions from each of forty organisms that were selected based on a known high incidence of cytotoxic compounds in their extracts. The rationale behind organism selection was to determine if our fractionation method is effective at enabling observation of phenotypic activity in the presence of strong background cytotoxicity. Within the 160 fractions, 25% exhibited embryo toxicity whereas an additional 8% caused various other phenotypic responses 24 hours after treatment. We report here the results from one of the organisms displaying activity, the sponge *Xestospongia* cf. *carbonaria* collected in Palau, which caused a phenotype of abnormal notochord development and death in the primary screen. Three new pyridoacridine alkaloids **1**--**3** as well as the known compounds **4**--**6**, were isolated from a large scale extraction of this sponge. The pure compounds **1**--**6** were evaluated in the zebrafish assay, identifying amphimedine (**4**) as the agent responsible for the phenotypic response in the primary screen.

2. Results and Discussion
=========================

The specimen of *Xestospongia* cf. *carbonaria* was extracted with MeOH. The crude extract was separated on HP20SS resin according to a prefractionation protocol previously reported by this lab \[[@b11-marinedrugs-08-01769]\]. Subsequent bioassay-guided fractionation resulted in the isolation of the pyridoacridine alkaloids **1**--**3** as their respective trifluoroacetate salts, along with the known compounds amphimedine (**4**), neoamphimedine (**5**), and deoxyamphimedine (**6**). 1-Hydroxy-deoxyamphimedine (**1**) was obtained as a red-orange amorphous solid. A molecular ion in the positive HRESIMS spectrum at *m/z* 314.0945 corresponded to a molecular formula of C~19~H~12~N~3~O~2~ (Δ 4.8 ppm), which was isomeric with amphimedine (**4**) and neoamphimedine (**5**). The strong absorption bands at 3382 and 1687 cm^−1^ in the IR spectrum indicated that **1** contained a hydroxyl group and a conjugated carbonyl group. The structure of **1** was elucidated by interpretation of NMR data ([Table 1](#t1-marinedrugs-08-01769){ref-type="table"}) and comparison with spectral data for deoxyamphimedine (**6**). The only difference observed in the NMR data between **1** and **6** was in the A ring system. For **1**, two doublets and one doublet of doublets at δ~H~ 7.48 (*J* = 8.0 Hz), 8.45 (*J* = 8.0 Hz) and 7.91 (*J* = 8.0, 8.0 Hz) ppm, respectively, indicated an additional hydroxyl present at either C-1 or C-4. The position of the hydroxyl group was identified as C-1 based on a NOESY correlation between signals at δ~H~ 8.45 (H-4) and 9.13 (H-5) ppm. The gHMBC spectrum also supported the assignment of **1** as 1-hydroxy-deoxyamphimedine.

A molecular formula of C~19~H~12~N~3~O~2~ for 3-hydroxy-deoxyamphimedine (**2**) was consistent with both the HRESIMS (*m/z* 314.0938, \[M\]^+^, Δ 2.5 ppm) and with proton and carbon counts in the respective NMR spectra. Compound **2** is isomeric with **1** and showed a very similar IR spectrum suggesting the presence of a hydroxyl group (ν~max~ 3421 cm^−1^) and an iminoquinone (ν~max~ 1685 cm^−1^). ^1^H chemical shifts and coupling patterns for the A ring were different from those of **1**. The ^1^H NMR spectrum of **2** contained a broad doublet at δ~H~ 8.20 ppm (H-4, *J* = 2.5 Hz) and a doublet of doublets at δ~H~ 7.63 ppm (H-2, *J* = 9.0, 2.5 Hz) indicating that the hydroxyl was at C-3. Thus, the A ring in **2** was identified as being a 1, 3, 4-trisubstituted benzene, which marks the difference between **1** and **2.** A 1D NOESY experiment also showed a correlation between signals at δ~H~ 8.20 (H-4) and 9.00 ppm (H-5) in **2**, thus confirming the identity of **2** as 3-hydroxy-deoxyamphimedine.

The structure of debromopetrosamine (**3**) appeared in a review on marine pyridoacridine alkaloids \[[@b12-marinedrugs-08-01769]\], but the compound has never been formally described. The alkaloid **3** was isolated as a purple-blue amorphous solid and determined to have a molecular formula of C~21~H~18~N~3~O~2~ by HRESIMS (*m/z* 344.1415, \[M\]^+^, Δ 4.6 ppm). A strong and broad absorption band at 1682 cm^−1^ in the IR spectrum suggested that **3** contained multiple conjugated ketones. The gHSQC spectrum and ^1^H NMR data indicated seven aromatic protons, two methylene protons (δ~H~ 4.41, H-6) and nine *N*-methyl protons (δ~H~ 4.53, Me-14 and δ~H~ 3.84, Me-15, 16). The ^1^H chemical shifts and coupling patterns of ring A in **3** were nearly identical with those of amphimedine (**4**) and neoamphimedine (**5**). Ortho-coupled proton resonances at δ~H~ 8.75 (H-11) and δ~H~ 9.39 (H-12), along with a low-field proton at δ~H~ 9.72 (H-9) indicated **3** contained the same E ring pattern as deoxyamphimedine (**6**) although the ^1^H and ^13^C chemical shifts of Me-14 showed it was not attached to a quaternary nitrogen. The degenerate *N,N-*dimethyl proton singlets at δ~H~ 3.84 showed gHMBC correlations to an *N*-methyl carbon at δ~C~ 54.1, an aromatic quaternary carbon at δ~C~ 115.1 (C-7a), the methylene carbon at δ~C~ 71.4 (C-6) and a weak long-range correlation to δ~C~ 187.2 (C-5). Additionally, the gHMBC spectrum showed correlations from methylene protons δ~H~ 4.41 (H-6) to the degenerate *N*-methyl carbons C-15 and C-16 (δ~C~ 54.1), a quaternary aromatic carbon at δ~C~ 115.8 (C-4b), as well as the carbonyl at δ~C~ 187.2 (C-5). The gHMBC correlations between H-4 and C-4b; H-9 and C-8; H-11 and C12a; and H12 to C12b and C-8a elucidated the connectivities of the A, B, C, and D rings. COSY correlations from δ~H~ 9.72 (H-9) to δ~H~ 8.75 (H-11); from δ~H~ 9.27 (H-4) to δ~H~ 7.84 (H-3); from δ~H~ 8.19 (H-1) to δ~H~ 7.84 (H-3) and δ~H~ 7.73 (H-2); from δ~H~ 4.41 (H -6) to δ~H~ 3.84 (H -15, H-16); and from δ~H~ 8.75 (H-11) to δ~H~ 9.39 (H -12) and δ~H~ 4.53 (H -14) further confirmed the carbon connections. Based on these assignments and comparison of spectral data with those from the known compounds petrosamine \[[@b13-marinedrugs-08-01769]\] and petrosamine B \[[@b14-marinedrugs-08-01769]\], we conclude that **3** is debromopetrosamine.

Of the pure compounds (**1**--**6**) isolated from this sponge, only amphimedine (**4**) showed a phenotype in the zebrafish assay at 30 μM. Embryos exposed to amphimedine (**4**) exhibited necrosis, pericardial edema and an enlarged yolk with thin extension ([Figure 2B, D](#f2-marinedrugs-08-01769){ref-type="fig"}). The embryos also appeared short and grainy, with an extended heart, weak heartbeat, no circulation, and irregular curvature of the tail ([Figure 2B, D](#f2-marinedrugs-08-01769){ref-type="fig"}). In order to further characterize the phenotypes induced by amphimedine (**4**), a series of *in situ* hybridization experiments were carried out that utilized digoxigenin-labeled antisense RNA probes against various regulatory genes involved in development and differentiation. These studies enabled selective high-contrast imaging of various organs. Treated embryos showed wavy notochord, spinal cord and abnormally shaped somites after imaging of *ntl*, *hnf6* and *myoD*, respectively ([Figure 3B, D, F](#f3-marinedrugs-08-01769){ref-type="fig"}). They also lack pectoral fin buds, have slightly smaller eyes and shortened brain regions as shown by the imaging of known brain markers such as *dlx2*, *otx2*, *fgf8* and *zash1a* ([Figure 3H, J, L, N, P, R](#f3-marinedrugs-08-01769){ref-type="fig"}). The variety and severity of phenotypic responses induced by amphimedine (**4**) suggest interference with a fundamental process in embryonic development or action against multiple systems. Unfortunately, at this time it is not possible to infer from the pattern of activities observed which specific targets amphimedine (**4**) might be modulating.

Since the first pyridoacridine, amphimedine (**4**) was identified in 1983 \[[@b15-marinedrugs-08-01769]\], over a hundred pyridoacridine alkaloids have been isolated from marine sources \[[@b16-marinedrugs-08-01769]\]. The bioactivity most often reported for pyridoacridine molecules has been cytotoxicity \[[@b17-marinedrugs-08-01769]--[@b22-marinedrugs-08-01769]\], although a wide array of other biological activities have also been documented, such as antimicrobial \[[@b23-marinedrugs-08-01769],[@b24-marinedrugs-08-01769]\], anti-viral \[[@b25-marinedrugs-08-01769]\], and DNA-directed activities \[[@b26-marinedrugs-08-01769]\]. Neoamphimedine (**5**), a known topoisomerase II inhibitor \[[@b17-marinedrugs-08-01769]\], was not active in the zebrafish screen, which is consistent with our observations that other known top2 inhibitors, including etoposide, daunorubicin and doxorubicin show no phenotype, illustrating both the selectivity of the assay and the remarkable versatility of the pyridoacridine family. From a structure activity viewpoint, it is clear that minor structural differences can have a marked effect on the biological activity of the pyridoacridine class of compounds. It is worth noting that amphimedine (**4**), despite its low abundance relative to the toxic pyridoacridines also present in the extract, displayed observable activity in fairly crude fractions. This suggests that modest fractionation schemes that can be carried out in parallel with many extracts at low cost can be sufficient to allow detection of compounds causing interesting phenotypes, even in the presence of cytotoxic compounds.

3. Experimental Section
=======================

3.1. General Experimental Procedures
------------------------------------

UV spectra were acquired in spectroscopy grade MeOH using a Hewlett-Packard 8452A diode array spectrophotometer. IR spectra were recorded on a JASCO FT/IR-420 spectrometer. NMR data for compounds **1**--**3** were acquired using a Varian INOVA 500 (^1^H 500 MHz, ^13^C 125 MHz) NMR spectrometer with a 3mm Nalorac MDBG probe or Varian INOVA 600 (^1^H 600 MHz, ^13^C 150 MHz) NMR spectrometer with a 5 mm Cold Probe for compound **2** referenced to residual solvent (δ~H~ 2.49, δ~C~ 39.51 for DMSO-*d~6~*; δ~H~ 3.30, δ~C~ 49.15 for CD~3~OD; and δ~H~ 1.94, δ~C~ 118.69 for CD~3~CN). High-resolution ESIMS analyses were performed on a Micromass Q-tof micro. Initial purification was performed on HP20SS resin. HPLC was performed on an Agilent 1100 system using Luna Phenyl-Hexyl (Phenomenex, Inc.) (250 × 10 mm, 5 μm; 250 × 4.6 mm, 5 μm) and Luna C~18~ (Phenomenex, Inc.)(250 × 4.6 mm, 5 μm) columns.

3.2. Biological Material
------------------------

In order to obtain sufficient quantity of metabolites for biological testing, a large-scale collection of the source sponge was conducted. This sponge is identical to the material, *Xestospongia* cf. *carbonaria,* from which we previously reported the isolation of neoamphimedine \[[@b19-marinedrugs-08-01769]\]. This sponge is readily distinguished by its unique growth form, dark green staining pigmentation, and habitat. There has been confusion over its taxonomic placement, and it appears in the literature under several genus names including *Amphimedon, Axinyssa, Neopetrosia, Pellina,* and *Xestospongia*. Further investigation is needed to determine the correct taxonomic assignment of this sponge.

3.3. Extraction and Isolation
-----------------------------

The *Xestospongia* cf*. carbonaria* specimen (1.206 kg) was extracted with 100% MeOH (3 × 1.8 L) to yield 54.26 g of crude extract. The crude extract was adsorbed on a 450 × 75 mm column packed with 80 g HP20SS resin that was sequentially eluted with 2 L each of water (FW), 25% (F1), 50% (F2), 75% (F3), and 100% (F4) IPA in water followed by 100% MeOH (F5). Fraction F1 (1.06 g) was partitioned between CHCl~3~ (3 **×** 200 mL) and 70% MeOH (aq; 200 mL). The dried aqueous MeOH phase was further fractionated by HPLC phenyl-hexyl employing MeOH/aqueous TFA (0.1%) gradients resulting in the isolation of compound **1** (1.0 mg), **2** (0.8 mg), **3** (3.0 mg), and deoxyamphimedine (**6**, 10.1 mg). Purification of the HP20SS F2 fraction yielded amphimedine (**4**, 1.2 mg) and neoamphimedine (**5**, 5.1 mg). Compounds **4**--**6** were identified by comparison to known standards.

*1-Hydroxy-deoxyamphimedine* (**1**): Trifluoroacetate salt; red-orange amorphous solid; UV (MeOH) λ~max~ (log ɛ) 204 (4.51), 246 (4.35), 286 (sh, 4.16), 392 (3.92) nm; IR (film) ν~max~ 3382, 2925, 2854, 1687, 1598, 1507, 1206, 1136, 801, 723 cm^−1^; ^1^H NMR and ^13^C NMR data, see [Table 1](#t1-marinedrugs-08-01769){ref-type="table"}; HRESIMS *m/z*314.0945 \[M\] ^+^(calcd for C ~19~H~12~N~3~O~2~, 314.0930).

*3-Hydroxy-deoxyamphimedine* (**2**): Trifluoroacetate salt; orange-yellow amorphous solid; UV (MeOH) λ~max~ (log ɛ) 206 (4.95), 244 (4.94), 394 (3.34), 488 (3.24) nm; IR (film) ν~max~ 3421, 2925, 1685, 1505, 1443, 1210, 1139, 844, 803, 724 cm^−1^; ^1^H NMR and ^13^C NMR data, see [Table 1](#t1-marinedrugs-08-01769){ref-type="table"}; HRESIMS *m/z*314.0938 \[M\] ^+^(calcd for C ~19~H~12~N~3~O~2~, 314.0930).

*Debromopetrosamine* (**3**): Trifluoroacetate salt; purple-blue amorphous solid; UV (MeOH) λ~max~ (log ɛ) 216 (4.49), 282 (4.74), 374 (3.38), 592 (3.15) nm; IR (film) ν~max~ 3063, 1682, 1648, 1588, 1498, 1206, 1129, 801, 722 cm^−1^; ^1^H NMR and ^13^C NMR data, see [Table 1](#t1-marinedrugs-08-01769){ref-type="table"}; HRESIMS *m/z* 344.1415 \[M\]^+^ (calcd for C~21~H~18~N~3~O~2~, 344.1399).

3.4. Zebrafish Screen
---------------------

*Danio rerio* (zebrafish) were maintained as previously described \[[@b27-marinedrugs-08-01769]\]. Fertilized embryos were collected following natural spawnings in 2X PTU (1X E3 medium, 30.4 mg/L phenylthiouera). Embryos were periodically checked for death and developmental delay. At seven hours post-fertilization (hpf), embryos were arrayed in 96-well plates at 1 embryo/well. Pure compounds were then added to the desired concentration, with dimethyl sulfoxide (DMSO) as vehicle control. DMSO was kept at 0.5% of the total assay volume. Embryos were grown at 28.5 °C and examined visually with a dissecting microscope at 1, 2, 3 and 6 days post treatment. Early toxicity was noted by examining the embryos at 1, 5, and 17 hours post treatment. Embryos were photographed live. All experiments were repeated at least twice, in duplicate.

*In situ* hybridizations were performed as previously described using digoxigenin-labeled riboprobes for *crx* (cone rod homeobox), *dlx2* (distal-less homeobox protein 2), *fgf8* (fibroblast growth factor 8), *hnf6* (hepatocyte nuclear factor-6), *id6* (inhibitor of DNA-binding/differentiation 6), *myoD* (myogenic differentiation1), *ntl* (no tail), *otx2* (orthodentical homeobox protein 2) and *zash1a* (zebrafish achaete/scute homologue 1a) \[[@b28-marinedrugs-08-01769]\]. Embryos were photographed with an Olympus SZX12 digital camera.
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![Amphimedine-treated embryos exhibit heart, yolk and body shape defects. Treatment of embryos seven hours post-fertilization (hpf) with 30 μM amphimedine (amp) resulted in pericardial edema (arrow), extended heart (arrow head), enlarged yolk with thin extension (\*), curving of the body and general necrosis at 24 hours post-treatment (hpt; B) and 48 hpt (D) compared to the DMSO-treated controls (A and C, respectively).](marinedrugs-08-01769f2){#f2-marinedrugs-08-01769}

###### 

Additional developmental defects resulting from amphimedine treatment. *In situ* hybridization was performed on control (A, C, E, G, I, K, M, O, Q) and treated (B, D, F, H, J, L, N, P, R) embryos harvested at 24 h (*ntl*, *hnf6*, *myoD*, *dlx2*, *otx2*, *fgf8*, *zash1a*, *id6*) or 48 h (*crx*) post treatment. Scale bars, 50 μM. not, notochord; sc, spinal cord; som, somites; pa, pharyngeal arches; fb, forebrain; mb, midbrain; mhb, mid/hindbrain boundary; hb, hindbrain; pfb, pectoral fin bud; e, eye.
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###### 

^1^H and ^13^C-NMR data of pyridoacridine alkaloids (**1**--**3**).

  Posn.   1                     2       3                                                                           
  ------- --------------------- ------- ------- --------------------- ------- ------- --------------------- ------- -------
  1                             156.1   C       8.39, d (9.0)         135.8   CH      8.19, d (9.0)         143.0   CH
  2       7.48, d (8.0)         116.5   CH      7.63, dd (9.0, 2.5)   124.3   CH      7.73, dd (9.0, 7.5)   128.4   CH
  3       7.91, dd (8.0, 8.0)   133.3   CH                            162.7   C       7.84, dd (8.0, 7.5)   133.5   CH
  4       8.45, d (8.0)         114.5   CH      8.20, d (2.5)         108.0   CH      9.27, d (8.0)         125.1   CH
  4a                            123.8   C                             126.6   C                             125.2   C
  4b                            137.9   C                             140.9   C                             115.8   C
  5       9.13, d (6.0)         121.8   CH      9.00, d (6.0)         122.9   CH                            187.2   C
  6       9.37, d (6.0)         150.2   CH      9.30, d (6.0)         151.4   CH      4.41, s               71.4    CH~2~
  7a                            147.0   C                             149.5   C                             115.1   C
  8                             180.0   C                             180.6   C                             161.0   C
  8a                            130.3   C                             130.8   C                             132.7   C
  9       9.87, s               146.0   CH      9.82, s               147.9   CH      9.72, s               145.9   CH
  11      9.40, d (6.5)         147.8   CH      9.17, d (6.5)         148.7   CH      8.75, d (6.5)         142.0   CH
  12      9.90, d (6.5)         123.5   CH      9.38, d (6.5)         124.1   CH      9.39, d (6.5)         122.9   CH
  12a                           147.9   C                             149.2   C                             143.5   C
  12b                           143.1   C                             145.5   C                             139.5   C
  12c                           120.1   C                             120.8   C                             129.9   C
  13a                           134.4   C                             141.5   C                             143.1   C
  14      4.57, s               48.3    CH~3~   4.58, s               49.3    CH~3~   4.53                  49.0    CH~3~
  15                                                                                  3.84, s (3H)          54.1    CH~3~
  16                                                                                  3.84, s (3H)          54.1    CH~3~

^13^C NMR data assigned based on the HSQC and HMBC in DMSO-*d~6~* (500 MHz).

^13^C NMR data assigned based on the HSQC and HMBC in CD~3~OD (600 MHz).

^13^C NMR data assigned based on the HSQC and HMBC in CD~3~CN (500 MHz).
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